ロード中...
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E‐mutant colorectal adenocarcinoma
The mitogen‐activated protein kinase (MAPK) pathway plays a central role in colorectal cancers (CRC). In particular, BRAF V600E‐mutant tumors, which represent around 10% of CRCs, are refractory to current therapies. Overexpression and secretion of serine peptidase inhibitor Kazal type 1 (SPINK1) are...
保存先:
| 出版年: | Mol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5792734/ https://ncbi.nlm.nih.gov/pubmed/29193645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12160 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|